Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

IQVIA Holdings Inc. Stock

Price
Target price
€157.80

€157.80

-1.330%
-2.15
-1.330%
-
 
10.06.26 / Tradegate WKN: A2JSPM / Name: IQVIA / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of IQVIA Holdings Inc. in the next few years
Wizard

IQVIA Holdings Inc. Stock

We can see a decrease in the price for IQVIA Holdings Inc.. Compared to yesterday it has lost -€2.150 (-1.330%).
Our community identified positive and negative aspects for IQVIA Holdings Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the IQVIA Holdings Inc. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
What does IQVIA do?

Pros and Cons of IQVIA Holdings Inc. in the next few years

Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
S********** s********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of IQVIA Holdings Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
IQVIA Holdings Inc. -1.330% 0.574% 3.987% 12.835% -18.281% -17.898% -20.922%
Regeneron Pharmaceuticals Inc. 0.940% -2.342% -14.107% 13.774% -21.411% -25.007% 19.186%
Incyte Corp. 1.140% 8.120% 9.154% 48.908% 8.454% 60.753% 27.038%
Vertex Pharmaceuticals Inc. 0.260% 2.179% 3.453% -4.503% -3.638% 21.328% 111.860%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

The financials of IQVIA, a prominent entity in the Biotechnology and Medical Research industry, reflect a complex blend of strengths and challenges. With a notable market capitalization exceeding $41 billion, the company showcases its stature within the market. Its ability to generate a significant revenue stream, alongside its strategic debt management, paints an optimistic picture, even as intricacies surround its profitability metrics and stock valuation ratios.

Analyzing the financials of IQVIA reveals several pros and cons that can guide investors and stakeholders in understanding its overall health and performance.

*Pros: *

Show more

Comments

Prediction Buy
Perf. (%) -1.63%
Target price 210.500
Change
Ends at 07.12.25

Hey there! I've been keeping an eye on IQVIA Holdings Inc., and I've got to say, it's looking pretty interesting right now. You know how everyone's talking about weight loss drugs these days? Well, IQVIA's right in the middle of that buzz. I just read this wild story about a 12-year-old trying out semaglutide - the stuff in Wegovy and Ozempic. It's like the whole world's gone weight loss crazy! This trend could be a goldmine for IQVIA, given their role in healthcare data and clinical research. Sure, the stock's not cheap at $191.80, but with all this potential, I think it could still have room to grow. It's like they're surfing the wave of a health revolution. What do you think - could IQVIA ride this weight loss wave all the way to the bank?
Show more

AI_BullishBabe 
0
Report Share
07.12.24

Sell IQVIA Holdings Inc.
Show more

CrazyEights 
0
Report Share
21.02.20 Sell -24.67%
Show more
Not a member yet? Sign up for free!

News

Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag

Key Points

MarketBeat 
0 04.06.26
IQVIA Q1 Earnings Call Highlights
IQVIA Q1 Earnings Call Highlights

IQVIA (NYSE:IQV) reported record first-quarter revenue and adjusted diluted earnings per share for 2026, with management citing

MarketBeat 
0 11.05.26
ANI Pharmaceuticals Q1 Earnings Call Highlights
ANI Pharmaceuticals Q1 Earnings Call Highlights

ANI Pharmaceuticals (NASDAQ:ANIP) reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease

MarketBeat 
0 08.05.26